Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-4055 in Refractory/Relapsed Hematologic Malignancies
NCT00405743Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- May 2006
- Primary completion
- May 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 6
01
Overview
Phase 2, open-label trial of elacytarabine in hematologic malignancy and acute myeloid leukemia (AML) (4 arms), sponsored by Clavis Pharma. Primary endpoints: Maximum Tolerated Dose, Pharmacokinetics and 1 more. Started May 2006; status: completed.
02
Drugs
elacytarabine
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00405743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405743.